Skip To Main Content
Yingni Lian on Muck Rack

Yingni Lian

As seen in: Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingni

Contact Yingni, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Individualized duration of adjuvant alectinib therapy and rechallenge efficacy in ALK-positive non-small cell lung cancer: a case report

|
By Junliang Chen, Yu Lan, Jun Chen, Zihan Zeng, Simin Feng, Meihan Wang, Yingni Lian, Chengye Chen, Tinghua Gao
| Frontiers
Abstract Background: Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is a distinct molecular subtype of cancer that typically affects younger patients and carries a high risk of central nervous system (CNS) metastases. Adjuvant alectinib therapy has demonstrated efficacy in prolonging disease-free survival; however, the optimal duration of adjuvant treatment remains undefined.
Open in Who Shared Issue with article?
See all 1 articles